259 related articles for article (PubMed ID: 23773409)
1. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update.
Hoskin PJ; Colombo A; Henry A; Niehoff P; Paulsen Hellebust T; Siebert FA; Kovacs G
Radiother Oncol; 2013 Jun; 107(3):325-32. PubMed ID: 23773409
[TBL] [Abstract][Full Text] [Related]
2. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
Kovács G; Pötter R; Loch T; Hammer J; Kolkman-Deurloo IK; de la Rosette JJ; Bertermann H
Radiother Oncol; 2005 Feb; 74(2):137-48. PubMed ID: 15734201
[TBL] [Abstract][Full Text] [Related]
3. GEC-ESTRO ACROP prostate brachytherapy guidelines.
Henry A; Pieters BR; André Siebert F; Hoskin P;
Radiother Oncol; 2022 Feb; 167():244-251. PubMed ID: 34999134
[TBL] [Abstract][Full Text] [Related]
4. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.
Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698
[TBL] [Abstract][Full Text] [Related]
5. High dose rate brachytherapy for prostate cancer.
Hoskin P
Cancer Radiother; 2008 Nov; 12(6-7):512-4. PubMed ID: 18755623
[TBL] [Abstract][Full Text] [Related]
6. Normal tissue dosimetric comparison between HDR prostate implant boost and conformal external beam radiotherapy boost: potential for dose escalation.
Hsu IC; Pickett B; Shinohara K; Krieg R; Roach M; Phillips T
Int J Radiat Oncol Biol Phys; 2000 Mar; 46(4):851-8. PubMed ID: 10705005
[TBL] [Abstract][Full Text] [Related]
7. High dose rate iridium-192 brachytherapy as a component of radical radiotherapy for the treatment of localised prostate cancer.
Chin YS; Bullard J; Bryant L; Bownes P; Ostler P; Hoskin PJ
Clin Oncol (R Coll Radiol); 2006 Aug; 18(6):474-9. PubMed ID: 16909971
[TBL] [Abstract][Full Text] [Related]
8. Results of multiparametric transrectal ultrasound-based focal high-dose-rate dose escalation combined with supplementary external beam irradiation in intermediate- and high-risk localized prostate cancer patients.
Kovács G; Müller K; Soror T; Melchert C; Guo X; Jocham D; Merseburger A
Brachytherapy; 2017; 16(2):277-281. PubMed ID: 27964906
[TBL] [Abstract][Full Text] [Related]
9. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.
Salembier C; Lavagnini P; Nickers P; Mangili P; Rijnders A; Polo A; Venselaar J; Hoskin P;
Radiother Oncol; 2007 Apr; 83(1):3-10. PubMed ID: 17321620
[TBL] [Abstract][Full Text] [Related]
10. Learning curve of MRI-based planning for high-dose-rate brachytherapy for prostate cancer.
Buus S; Rylander S; Hokland S; Søndergaard CS; Pedersen EM; Tanderup K; Bentzen L
Brachytherapy; 2016; 15(4):426-434. PubMed ID: 27220699
[TBL] [Abstract][Full Text] [Related]
11. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.
Stromberg J; Martinez A; Gonzalez J; Edmundson G; Ohanian N; Vicini F; Hollander J; Gustafson G; Spencer W; Yan Di
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):161-71. PubMed ID: 7543891
[TBL] [Abstract][Full Text] [Related]
12. [High-dose rate iridium-192 brachytherapy combined with external beam radiotherapy for localized prostate cancer].
Kasahara K; Inoue K; Karashima T; Inoue Y; Kariya S; Inomata T; Yoshida S; Shuin T
Nihon Hinyokika Gakkai Zasshi; 2001 Jul; 92(5):572-8. PubMed ID: 11517568
[TBL] [Abstract][Full Text] [Related]
13. [Permanent implant prostate cancer brachytherapy: 2013 state-of-the art].
Cosset JM; Hannoun-Lévi JM; Peiffert D; Delannes M; Pommier P; Pierrat N; Nickers P; Thomas L; Chauveinc L
Cancer Radiother; 2013 Apr; 17(2):111-7. PubMed ID: 23478488
[TBL] [Abstract][Full Text] [Related]
14. [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].
Cosset JM; Haie-Meder C
Cancer Radiother; 2005 Dec; 9(8):610-9. PubMed ID: 16226473
[TBL] [Abstract][Full Text] [Related]
15. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB; Småstuen MC; Brabrand S; Fosså SD; Kaasa S; Tafjord G; Russnes KM; Hellebust TP; Lilleby W
Radiother Oncol; 2019 Mar; 132():211-217. PubMed ID: 30389241
[TBL] [Abstract][Full Text] [Related]
16. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
Keam SP; Halse H; Nguyen T; Wang M; Van Kooten Losio N; Mitchell C; Caramia F; Byrne DJ; Haupt S; Ryland G; Darcy PK; Sandhu S; Blombery P; Haupt Y; Williams SG; Neeson PJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581061
[TBL] [Abstract][Full Text] [Related]
17. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
18. A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Joseph N; Taylor C; O'Hara C; Choudhury A; Elliott T; Logue J; Wylie J
Radiother Oncol; 2016 Nov; 121(2):299-303. PubMed ID: 28029404
[TBL] [Abstract][Full Text] [Related]
19. A systematic overview of radiation therapy effects in prostate cancer.
Nilsson S; Norlén BJ; Widmark A
Acta Oncol; 2004; 43(4):316-81. PubMed ID: 15303499
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321.
Hsu IC; Bae K; Shinohara K; Pouliot J; Purdy J; Ibbott G; Speight J; Vigneault E; Ivker R; Sandler H
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):751-8. PubMed ID: 20207506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]